12 documents found, page 1 of 2
Prognostic and predictive value of primary tumour side in patients with RAS wil...
Arnold, D; Lueza, B; Douillard, J-Y; Peeters, M; Lenz, H-J; Venook, A; Heinemann, V; Van Cutsem, E; Pignon, J-P; Tabernero, J; Cervantes, ABACKGROUND: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different classes of targeted agents in patients with KRAS wild-type (wt) or RAS wt mCRC suggest that primary tumour locati...
Methylated free-circulating HPP1 DNA is an early response marker in patients wi...
Herbst, A; Vdovin, N; Gacesa, S; Philipp, A; Nagel, D; Holdt, LM; Op den Winkel, M; Heinemann, V; Stieber, P; Graeven, U; Reinacher-Schick, A; Arnold, DDetection of methylated free-circulating DNA (mfcDNA) for hyperplastic polyposis 1 (HPP1) in blood is correlated with a poor prognosis for patients with metastatic colorectal cancers (mCRC). Here, we analyzed the plasma levels of HPP1 mfcDNA in mCRC patients treated with a combination therapy containing a fluoropyrimidine, oxaliplatin and bevacizumab to test whether HPP1 mfcDNA is a suitable prognostic and resp...
ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A criti...
Beets, G; Sebag-Montefiore, D; Andritsch, E; Arnold, D; Beishon, M; Crul, M; Dekker, JW; Delgado-Bolton, R; Fléjou, JF; Grisold, W; Henning, G; Laghi, ABackground ECCO essential requirements for quality cancer care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to patients who have a specific tumour type. They are written by European experts representing all disciplines involved in cancer care. ERQCC papers give oncology teams, patients, policymakers and managers an overview of the elements need...
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival i...
Al-Batran, SE; Homann, N; Pauligk, C; Illerhaus, G; Martens, UM; Stoehlmacher, J; Schmalenberg, H; Luley, KB; Prasnikar, N; Egger, M; Probst, SIMPORTANCE: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. OBJECTIVE: To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and proceed to surgical resection. DESIGN, SETTING, AND PARTICIPANTS: The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxalipl...
Biosimilars: a position paper of the European Society for Medical Oncology, wit...
Tabernero, J; Vyas, M; Giuliani, R; Arnold, D; Cardoso, F; Casali, PG; Cervantes, A; Eggermont, AM; Eniu, A; Jassem, J; Pentheroudakis, G; Peters, Ssystems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. A critical consideration regarding the introduction of biosimilars into the clinic centres on the required information concerning all the respective procedures. This position paper aims to describe the issues revolving around b...
Clinicopathological factors influencing outcome in metastatic colorectal cancer...
Goey, KK; Elias, SG; Hinke, A; van Oijen, MG; Punt, CJ; Hegewisch-Becker, S; Arnold, D; Koopman, MBACKGROUND: The CAIRO3 and AIO 0207 trials demonstrated the efficacy of fluoropyrimidine plus bevacizumab (FP+Bev) maintenance treatment in metastatic colorectal cancer (mCRC) patients. In this individual patient data meta-analysis with updated follow-up, we aim to provide more precise estimates of treatment effects and to identify subgroups that benefit most from maintenance treatment or observation. METHODS: ...
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and f...
Glynne-Jones, R; Wyrwicz, L; Tiret, E; Brown, G; Rödel, C; Cervantes, A; Arnold, D
Treatment approach in patients with hyperbilirubinemia secondary to liver metas...
Quidde, J; Azémar, M; Bokemeyer, C; Arnold, D; Stein, ABACKGROUND: Treatment of patients with severe liver dysfunction including hyperbilirubinemia secondary to liver metastases of gastrointestinal (GI) cancer is challenging. Regimen of oxaliplatin and fluoropyrimidine (FP)/folinic acid (FA) ± a monoclonal antibody (moAb), represents a feasible option considering the pharmacokinetics. Clinical data on the respective dosage and tolerability are limited and no recomm...
Second St. Gallen European Organisation for Research and Treatment of Cancer Ga...
Lutz, MP; Zalcberg, JR; Glynne-Jones, R; Ruers, T; Ducreux, M; Arnold, D; Aust, D; Brown, G; Bujko, K; Cunningham, C; Evrard, S; Folprecht, GPrimary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging...
Intraperitoneal bevacizumab for control of malignant ascites due to advanced-st...
Jordan, K; Luetkens, T; Gog, C; Killing, B; Arnold, D; Hinke, A; Stahl, M; Freier, W; Rüssel, J; Atanackovic, D; Hegewisch-Becker, SPURPOSE: Malignant ascites is debilitating for patients with advanced cancer. As shown previously, tumour cell production of vascular endothelial growth factor might be a major cause of the formation of malignant ascites. Intraperitoneal bevacizumab could therefore be an option for symptom control in refractory ascites. PATIENTS AND METHODS: Patients with advanced gastrointestinal cancer and malignant ascites w...